Please login to the form below

Not currently logged in
Email:
Password:

Brilique

This page shows the latest Brilique news and features for those working in and with pharma, biotech and healthcare.

NICE backs expanded use of Brilique in final guidance

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack. NICE has recommended AstraZeneca's Brilique (ticagrelor) as a long-term treatment for patients who have had a heart ... Brilique brought in sales of $395m in the first half of

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • The evolution of IQWiG in Germany’s drug pricing policy The evolution of IQWiG in Germany’s drug pricing policy

    This includes MSD's hepatitis C drug Victrelis and AstraZeneca's blood clotting drug Brilique. ... With Brilique, IQWiG wanted to split the patient population into four different sub-populations, from which only one received a label of additional benefit.

  • Drug pricing in Ireland Drug pricing in Ireland

    It said that up to 10 new medicines that had proved cost effective through HTA – including Brilique, Gileyna, Sycrest, Incivo and Victrelis – were still not being reimbursed.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • AZ names Brilique lead in Spain AZ names Brilique lead in Spain

    In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be ... Gribble has been with AstraZeneca in Spain

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics